title: Effect of oral D-tagatose on liver volume and hepatic glycogen accumulation in healthy male volunteers.
abstract: Standard toxicity tests with high levels of D-tagatose showed a reversible enlargement of the liver in Sprague-Dawley rats without increase of liver enzymes. The present study tests the hypotheses that partial substitution of dietary sucrose by D-tagatose for 28 days increases the volume of human liver and the concentration of liver glycogen. Twelve healthy, male volunteers were studied in a double-blind crossover study with ingestion of D-tagatose (3x15 g daily) and placebo (sucrose, 3x15 g daily) for periods of 28 days each. Liver volume and glycogen concentration have been determined by magnetic resonance (MR) imaging and spectroscopy, which were accompanied by routine medical examinations. MR examinations before and after the treatments revealed no effects (P>0.05) of treatment, period, or subject for changes in liver volume or glycogen concentration. A steady increase of liver volumes, independent of the D-tagatose or placebo intake, has been observed over the study in parallel with a slight increase in body weight. The treatment with D-tagatose was not associated with clinically relevant changes of the examined clinico-chemical and hematological parameters, including liver enzymes and uric acid.
authors.affiliation: Department of Clinical Research, MR-Spectroscopy & Methodology, University & Inselspital Bern, CH-3010 Bern, Switzerland. chris.boesch@insel.ch
authors.forename: C
authors.initials: C
authors.lastname: Boesch
authors.forename: M
authors.initials: M
authors.lastname: Ith
authors.forename: B
authors.initials: B
authors.lastname: Jung
authors.forename: K
authors.initials: K
authors.lastname: Bruegger
authors.forename: S
authors.initials: S
authors.lastname: Erban
authors.forename: I
authors.initials: I
authors.lastname: Diamantis
authors.forename: R
authors.initials: R
authors.lastname: Kreis
authors.forename: A
authors.initials: A
authors.lastname: Bär
mesh_terms: D000284:Administration, Oral; D000328:Adult; D018592:Cross-Over Studies; D004311:Double-Blind Method; D006601:Hexoses / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007502:Iron Chelating Agents / Q000008:administration & dosage / Q000009:adverse effects*; D008099:Liver / Q000033:anatomy & histology / Q000187:drug effects*; D008112:Liver Glycogen / Q000378:metabolism*; D008297:Male; D010919:Placebos; D019518:Postprandial Period; D013395:Sucrose / Q000008:administration & dosage
chemical_list: D006601:Hexoses; D007502:Iron Chelating Agents; D008112:Liver Glycogen; D010919:Placebos; D013395:Sucrose; C030192:tagatose